Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019.

Kissling E, Rose A, Emborg HD, Gherasim A, Pebody R, Pozo F, Trebbien R, Mazagatos C, Whitaker H, Valenciano M, European Ive Group.

Euro Surveill. 2019 Feb;24(8). doi: 10.2807/1560-7917.ES.2019.24.1900121.

2.

Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically attended influenza: Results of the European I-MOVE multicentre test-negative case-control study, 2011/2012-2016/2017.

Valenciano M, Kissling E, Larrauri A, Nunes B, Pitigoi D, O'Donnell J, Reuss A, Horváth JK, Paradowska-Stankiewicz I, Rizzo C, Falchi A, Daviaud I, Brytting M, Meijer A, Kaic B, Gherasim A, Machado A, Ivanciuc A, Domegan L, Schweiger B, Ferenczi A, Korczyńska M, Bella A, Vilcu AM, Mosnier A, Zakikhany K, de Lange M, Kurečić Filipovićović S, Johansen K, Moren A; I-MOVE primary care multicentre case-control team.

Influenza Other Respir Viruses. 2018 Apr 16. doi: 10.1111/irv.12562. [Epub ahead of print]

3.

Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies.

Rondy M, Kissling E, Emborg HD, Gherasim A, Pebody R, Trebbien R, Pozo F, Larrauri A, McMenamin J, Valenciano M; I-MOVE/I-MOVE+ group.

Euro Surveill. 2018 Mar;23(9). doi: 10.2807/1560-7917.ES.2018.23.9.18-00086.

4.

2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children.

Kissling E, Valenciano M, Pozo F, Vilcu AM, Reuss A, Rizzo C, Larrauri A, Horváth JK, Brytting M, Domegan L, Korczyńska M, Meijer A, Machado A, Ivanciuc A, Višekruna Vučina V, van der Werf S, Schweiger B, Bella A, Gherasim A, Ferenczi A, Zakikhany K, O Donnell J, Paradowska-Stankiewicz I, Dijkstra F, Guiomar R, Lazar M, Kurečić Filipović S, Johansen K, Moren A; I-MOVE/I-MOVE+ study team.

Influenza Other Respir Viruses. 2018 Jul;12(4):423-437. doi: 10.1111/irv.12520. Epub 2018 Mar 14.

5.

Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe.

Kissling E, Rondy M; I-MOVE/I-MOVE+ study team.

Euro Surveill. 2017 Feb 16;22(7). pii: 30464. doi: 10.2807/1560-7917.ES.2017.22.7.30464.

6.

Vaccine Effectiveness of Polysaccharide Vaccines Against Clinical Meningitis - Niamey, Niger, June 2015.

Rondy M, Issifou D, Ibrahim AS, Maman Z, Kadade G, Omou H, Fati S, Kissling E, Meyer S, Ronveaux O.

PLoS Curr. 2016 Apr 18;8. pii: ecurrents.outbreaks.5d6e9c1d071a2088109c242771b68886. doi: 10.1371/currents.outbreaks.5d6e9c1d071a2088109c242771b68886.

7.

I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?

Kissling E, Nunes B, Robertson C, Valenciano M, Reuss A, Larrauri A, Cohen JM, Oroszi B, Rizzo C, Machado A, Pitigoi D, Domegan L, Paradowska-Stankiewicz I, Buchholz U, Gherasim A, Daviaud I, Horváth JK, Bella A, Lupulescu E, O Donnell J, Korczyńska M, Moren A; I-MOVE case–control study team.

Euro Surveill. 2016 Apr 21;21(16). doi: 10.2807/1560-7917.ES.2016.21.16.30201.

8.

Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.

Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horváth JK, Domegan L, Pitigoi D, Machado A, Paradowska-Stankiewicz IA, Bella A, Larrauri A, Ferenczi A; Joan O´Donell, Lazar M, Pechirra P, Korczyńska MR, Pozo F, Moren A; I-MOVE multicentre case-control team.

Euro Surveill. 2016;21(7):pii=30139. doi: 10.2807/1560-7917.ES.2016.21.7.30139. Erratum in: Euro Surveill. 2016;21(8). doi: 10.2807/1560-7917.ES.2016.21.8.30145.

9.

The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2).

Valenciano M, Kissling E, Reuss A, Jiménez-Jorge S, Horváth JK, Donnell JM, Pitigoi D, Machado A, Pozo F; I-MOVE Multicentre Case Control Study Team.

Vaccine. 2015 Jun 4;33(24):2813-22. doi: 10.1016/j.vaccine.2015.04.012. Epub 2015 Apr 28.

10.
11.

I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe.

Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, Stefanoff P, Nunes B, Pitigoi D, Larrauri A, Daviaud I, Horvath JK, O'Donnell J, Seyler T, Paradowska-Stankiewicz IA, Pechirra P, Ivanciuc AE, Jiménez-Jorge S, Savulescu C, Ciancio BC, Moren A.

PLoS One. 2011;6(11):e27622. doi: 10.1371/journal.pone.0027622. Epub 2011 Nov 15.

12.

Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study.

Valenciano M, Kissling E, Cohen JM, Oroszi B, Barret AS, Rizzo C, Nunes B, Pitigoi D, Larrauri Cámara A, Mosnier A, Horvath JK, O'Donnell J, Bella A, Guiomar R, Lupulescu E, Savulescu C, Ciancio BC, Kramarz P, Moren A.

PLoS Med. 2011 Jan;8(1):e1000388. doi: 10.1371/journal.pmed.1000388. Epub 2011 Jan 11.

13.

Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges.

Hanquet G, Lernout T, Vergison A, Verhaegen J, Kissling E, Tuerlinckx D, Malfroot A, Swennen B, Sabbe M; Belgian IPD Scientific Committee.

Vaccine. 2011 Apr 5;29(16):2856-64. doi: 10.1016/j.vaccine.2011.02.016. Epub 2011 Feb 19.

PMID:
21342667
14.

Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks.

Valenciano M, Kissling E, Ciancio BC, Moren A.

Vaccine. 2010 Oct 28;28(46):7381-8. doi: 10.1016/j.vaccine.2010.09.010. Epub 2010 Sep 17.

PMID:
20851086
15.

Pneumococcal serotypes in children in 4 European countries.

Hanquet G, Kissling E, Fenoll A, George R, Lepoutre A, Lernout T, Tarragó D, Varon E, Verhaegen J.

Emerg Infect Dis. 2010 Sep;16(9):1428-39. doi: 10.3201/eid1609.100102.

16.

Surveillance of invasive pneumococcal disease in 30 EU countries: Towards a European system?

Hanquet G, Perrocheau A, Kissling E, Bruhl DL, Tarragó D, Stuart J, Stefanoff P, Heuberger S, Kriz P, Vergison A, de Greeff SC, Amato-Gauci A, Celentano LP; ECDC Country Experts for Pneumococcal Disease.

Vaccine. 2010 May 21;28(23):3920-8. doi: 10.1016/j.vaccine.2010.03.069. Epub 2010 Apr 13.

PMID:
20394721
17.

Immunologic response of unvaccinated workers exposed to anthrax, Belgium.

Wattiau P, Govaerts M, Frangoulidis D, Fretin D, Kissling E, Van Hessche M, China B, Poncin M, Pirenne Y, Hanquet G.

Emerg Infect Dis. 2009 Oct;15(10):1637-40. doi: 10.3201/eid1510.081717.

18.

Fisherfolk are among groups most at risk of HIV: cross-country analysis of prevalence and numbers infected.

Kissling E, Allison EH, Seeley JA, Russell S, Bachmann M, Musgrave SD, Heck S.

AIDS. 2005 Nov 18;19(17):1939-46. Review. No abstract available.

PMID:
16260899

Supplemental Content

Loading ...
Support Center